Antiplatelet medications and their indications in preventing and treating coronary thrombosis

Annals of Medicine

Volumn 32, Issue 8, 2000, Pages 561-571

  Van De Graaff, E ^a   Steinhubl, S R ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes; Aspirin; Blood platelets; Coronary disease; Coronary thrombosis; Myocardial ischaemia; Platelet aggregation; Platelet aggregation inhibitors; Platelet glycoprotein GPIIb IIIa complex

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DEXTRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; SULFINPYRAZONE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD DYSCRASIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

EID: 0033647258     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008998836     Document Type: Article

References (76)

1. Experience with anticoagulants
2. Acetylsalicylic acid, possible preventive of coronary thrombosis
3. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis
4. Clinical features of sudden obstruction of the coronary arteries
5. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
6. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death
7. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
8. The pathogenesis of coronary artery disease and the acute coronary syndromes (2)
9. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
10. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
11. A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction
12. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
13. Aspirin
14. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
15. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
16. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
17. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
18. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit
19. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration
20. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel
21. Thrombotic thrombocytopenic purpura after stenting and ticlopidine
22. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting
23. Thrombotic thrombocytopenic purpura associated with clopidogrel
24. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
25. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
26. Abciximab (7E3) pharmacodynamics demonstrates an extended and gradual recover from GPIIb/IIIa blockade
27. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
28. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
29. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
30. Randomised trial of prophylactic daily aspirin in British male doctors
31. Final report on the aspirin component of the ongoing physicians' health study
32. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
33. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
34. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
35. Prognostic value of the admission electrocardiogram in acute coronary syndromes
36. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
37. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial
38. Aspirin, heparin, or both to treat acute unstable angina
39. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization
40. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial
41. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
42. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
43. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
44. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
45. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
46. Randomised placebo-controlled trial of abciximab before and during coronary interventions in refractory unstable angina: The CAPTURE study
47. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial In
48. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither
49. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: A meta-analysis
50. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators
51. Thrombosis in unstable angina: Pathologic aspects
52. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
53. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 Trial
54. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
55. Angiographic follow-up after placement of a self-expanding coronary artery stent
56. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
57. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty
58. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty
59. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
60. Ticlopidine and clopidogrel
61. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
62. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study
63. A clinical trial comparing three anti-thrombotic regimens following coronary-artery stenting
64. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
65. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans
66. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
67. Ticlid or plavix post-stent (TOPPS): Randomization to 2 weeks of treatment
68. Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99
69. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
70. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Ste
71. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II
72. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
73. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
74. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized efficacy stu
75. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty
76. Acute platelet inhibition with abciximab does not reduce instent restenosis (ERASER Study)